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Summary
A profound inflammatory response is initiated following traumatic
brain injury (TBI). It has been proposed that serum IL-6 levels may serve
as a marker for the severity of the injury. Using the rat impact-accelera-
tion model of TBI, the study examined whether drugs which are able to
inhibit neurogenic inflammation (capsaicin, NK1 antagonist), might in-
fluence the post-traumatic inflammatory response. In non-treated animals,
TBI resulted in a significant increase in serum IL-6 levels. However, in
animals pre-treated with capsaicin prior to injury, or treated with an NK1
antagonist following injury, this rise in IL-6 levels was not observed. We
conclude that the inhibition of neurogenic inflammation may attenuate
the inflammatory reaction associated with TBI, and help improve out-
come.
Introduction
Traumatic brain injury (TBI) results in a profound inflammatory re-
sponse within the central nervous system, which is characterised by the
increased production of a number of pro-inflammatory mediators, includ-
ing tumour necrosis factor alpha, interleukin-1beta and interleukin-6 (IL-
6) (1). These mediators are considered to have both detrimental and
beneficial effects in terms of neural outcome following TBI. On one hand
they contribute to neuronal cell death and dysfunction, whilst on the other
they establish the foundation for reparative processes. Whilst the tissue
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levels of all these mediators increase following TBI, these changes are
not directly reflected by changes in serum levels (2). Of these mediators,
IL-6 is the only one where raised serum levels are readily detected fol-
lowing TBI. It has been proposed that increased blood levels of IL-6
following trauma may correlate with severity of injury and outcome (3,
4).
We have recently demonstrated that neurogenic inflammation plays a
significant role in the early response to TBI (5). The aim of the present
study was to examine whether agents that can modulate neurogenic in-
flammation have any affect on the subsequent cellular inflammatory re-
sponse, and in particular, post-trauma serum levels of IL-6. Two different
approaches were used to modulate neurogenic inflammation. Animals
were either subject to pre-treatment with capsaicin, which results in a
depletion of the peptide neurotransmitters, such as substance P, that are
normally released from nociceptive nerves, or post-injury treatment with
an NK1 tachykinin receptor antagonist. Two levels of injury were also
examined. Animals were subject to either severe closed head injury, using
the impact-acceleration model, or severe closed head injury followed by
30 minutes of hypoxia and hypotension.
Materials and Methods
Adult male Sprague-Dawley rats (350-450gms) were used in this study.
One group (n=20) were pre-treated with capsaicin over a 3-day period
(25, 50 and 50mg/kg), 14 days prior to injury or sham-injury, whilst the
second group (n=20) received an NK1 antagonist (N-acetyl tryptophan;
1:mol/kg) 30 min after injury or sham injury. Severe TBI was induced
using the impact-acceleration model of diffuse axonal injury as previ-
ously described in detail (6). Animals were anesthetized with isoflurane,
and a stainless steel disc fixed to the exposed skull. The animal was then
placed on a 10cm deep foam bed and injury induced by dropping a 450
gm brass weight a distance of two meters onto the disc. Animals were
killed by decapitation at 6 hours after injury, and serum samples were
collected.
For those animals also subject to hypoxia and hypotension following
injury (n=10), they were mechanically ventilated using a Harvard Rodent
Ventilator, whilst a femoral catheter enabled continuous mean arterial
blood pressure monitoring (MABP). Severe TBI was induced as described
above, immediately followed by the secondary insults which were main-
tained for 30min. Hypoxia was achieved by reducing inspired oxygen
content to produce a PAO2 between 30-40mmHg, whilst hypotension(MABP approx. 40mmHg) was induced by increasing the isoflurane and
NO2 concentrations. Animals were randomly assigned to receive injury
with or without post-injury treatment with an NK1 antagonist (n=5/group).
Animals were killed at 6 hours post-injury, and serum samples collected.
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Serum levels of IL-6 were determined using a sandwich enzyme-linked
immunoassay (ELISA) using a monoclonal antibody specific for rat IL-
6 (R&D Systems, Minneapolis Mn). Statistical analysis was performed
using the “Prism” statistics program (GraphPad Software, SanDiego Ca).
Significance was determined using a one-way analysis of variance (ANOVA),
with post-test analysis using Newman-Keuls multiple comparison test. A
p value of less than 0.05 was considered significant.
Results
In studies examining the effects of severe TBI (Fig. 1a), the sham-
injured animals exhibited low serum levels of IL-6 (103.7 ± 14.7pg/ml;
n=10). For those animals subject to injury without drug treatment, there
was a significant rise in serum IL-6 levels following severe TBI (289.3
± 75.9pg/ml; p < 0.01). However, in animals that received pre-treatment
with capsaicin, there was no significant difference in IL-6 levels as com-
pared to the sham-injured animals (92.7 ± 26.7pg/ml). Similarly, those
animals that received an NK1 antagonist 30mins after injury, showed no
significant rise in serum IL-6 levels (127.6 ± 11.7pg/ml).
In studies examining the effect of secondary insults due to hypoxia
and hypotension following severe TBI (Fig. 1b), the control animals again
showed an apparent elevation in serum IL-6 levels following injury (585.4
± 403.1pg/ml; n=5). However, those animals that received an NK1 an-
Figure 1. The effect of severe TBI (a), and severe TBI followed by 30 mins hypoxia
and hypotension (b) on serum IL-6 concentrations. Animals were subject to either
sham injury (Sham), TBI with no treatment (Control), TBI following pre-injury treat-
ment with capsaicin (Caps), or TBI plus post-injury treatment with an NK1 antago-
nist (NK1).
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tagonist following injury did not show an elevation in IL-6 levels despite
the double insult (82.4 ± 24.4pg/ml). Behavioural observations also indi-
cated that there were marked differences between the control and treated
groups. Following hypoxia, the time to spontaneous breathing was less in
the group treated with the NK1 antagonist (8.2 ± 0.9 mins versus 47 ±
33 mins; n=5; p < 0.05). Similarly, the time to animals demonstrating
purposeful behaviour (feeding, grooming, drinking) was significantly shorter
in the treated group (1.4 ± 0.2 hrs versus 4.2 ± 0.5 hrs; p < 0.05).
Conclusion
Severe TBI will result in a significant rise in serum IL-6 levels. How-
ever, our results indicate that drugs, which are able to modulate neuro-
genic inflammation, may prevent this rise in IL-6 levels. Pre-treatment
with capsaicin, which inhibits the role of the nociceptive nerves in neu-
rogenic inflammation, prevents post-trauma increases in IL-6 levels. However,
capsaicin cannot be used as an interventional treatment, since its acute
effects are pro-inflammatory. On the other hand, post-injury treatment
with an NK1 tachykinin receptor antagonist, which prevents the action of
substance P, also prevents the post-TBI rise in serum IL-6 levels. These
results suggest that neurogenic inflammation may influence the subse-
quent cellular inflammatory reaction associated with TBI, and that inhi-
bition of neurogenic inflammation may attenuate the inflammatory reac-
tion within the CNS. Given that serum IL-6 levels may be indicative of
injury severity, and likely outcome, these results suggest that the inhibi-
tion of neurogenic inflammation may be of clinical benefit in TBI.
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